Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Reducer stillesiddende adfærd under kræftbehandling - RedSedCan-undersøgelsen (RedSedCan)

28. september 2026 opdateret af: Mälardalen University

Summary

Reducing sedentary behavior during treatment is important to reduce the risk of future health problems in individuals undergoing cancer treatment. Therefore, the goal of this project is with a multicenter randomised controlled design investigate whether a digital support intervention during ongoing neo- or adjuvant cancer treatment for breast, prostate or colon cancer is effective in reducing sedentary lifestyle and improving well-being in the short and long term.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Description of the project

This project is about investigating the effect of a digital support intervention to reduce sedentary behavior in people with breast, prostate, or colorectal cancer during neo- or adjuvant cancer treatment. The digital support intervention has been developed with patients and researchers and consists of existing high-quality technology that provides support for setting and following goals. The people who use the digital support intervention also receive support from a physiotherapist to set goals for reduced sedentary time and get to choose which activities will replace the time spent sedentary.

The goal of the project

The goal of the project is to investigate the effects of a digital support intervention on reduced sedentary and well-being during ongoing cancer treatment, both in the short and long term. In addition, the project will study the health-economic effects, and climate benefits of using the digital support intervention. By focusing on reducing a sedentary lifestyle and replacing it with daily activities and/or physical activity, the health of individuals is expected to be positively affected in the short term through, for example, increased well-being and reduced side effects from cancer treatment, and the long term through a reduced risk of developing complications and new illness related to the cancer treatment, such as cardiovascular disease.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

210

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

      • Uppsala, Sverige
        • Rekruttering
        • Akademiska sjukhuset
      • Västerås, Sverige
        • Rekruttering
        • Västmanlands sjukhus

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Individuals diagnosed with breast, prostate, or colorectal cancer planned for or resently started neo- or adjuvant treatment (e.g. chemotherapy, radiotherapy, endocrine treatment) at the hospitals in Uppsala and Västerås, Sweden.

Exclusion Criteria:

  • Individuals diagnosed with dementia.
  • Individuals diagnosed with severe psychiatric disease.
  • Individuals with severe loss of vision, or communicative ability.
  • Individuals who cannot walk independently indoors with or without a walking aid.
  • Individuals completed treatment for other cancer diseases less than 12 months ago or not recovered from previous cancer treatment.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Støttende pleje
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Intervention

Participants receive a digital support intervention

The program consists of commercially available technologies, e.g. applications including behavour change techniques for reducing sedentary behavior (SB) (i.e. self-monitorization of physical activity, reminders for breaking SB/doing physical activity, and providing feedback on physical activity/breaks from SB) and a webpage containing information and tips (provided in short videos and text) regarding how to reduce SB. The participants will be receive help with setting goals for reducing time spent in sedentary/being active and help with planning for what activities to do to replace time in sedentary. Participants will then have access to the webpage and download the application to their smartphones. Follow-up meetings with the physiotherapist (digital or physical) will be conducted after 2, 8 and 12 weeks after start of intervention.

Ingen indgriben: Control

Control condition. Individuals receive the care as usual provided by the healthcare only.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Sedentary behavior time
Tidsramme: At baseline, 3-months, 6 months, 12 months and 24 months. Axivity is worn for 7 consecutive days at each measurement point.

The Axivity accelerometer is used for measuring the primary outcome of sedentary time, i.e. mean time spent in sedentary behavior/day.

At baseline, 3-months, 6 months, 12 months and 24 months. Axivity is worn for 7 consecutive days at each measurement point.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Sedentary behavior bouts
Tidsramme: At baseline, 3-months, 6 months, 12 months and 24 months. Axivity is worn for 7 consecutive days at each measurement point.

The Axivity accelerometer is used for measuring sedentary bouts, i.e. mean number of bouts/day and mean bouts time/day.

At baseline, 3-months, 6 months, 12 months and 24 months. Axivity is worn for 7 consecutive days at each measurement point.
Physical activity
Tidsramme: At baseline, 3-months, 6 months, 12 months and 24 months. Axivity is worn for 7 consecutive days at each measurement point.

The Axivity accelerometer is used for measuring physical activity mean time/day and mean time spent in low-, moderate and high intensity physical activity.

At baseline, 3-months, 6 months, 12 months and 24 months. Axivity is worn for 7 consecutive days at each measurement point.
Health-related quality of life
Tidsramme: At baseline, 3-months, 6 months, 12 months and 24 months.

Patient reported health related quality of life will be assessed with European Organization for Research and Treatment of Cancer QLQ C 30 and diagnose specific modules BR23, PR26 and CR29.

At baseline, 3-months, 6 months, 12 months and 24 months.
Health-related quality of life
Tidsramme: At baseline, 3-months, 6 months, 12 months and 24 months.

Patient reported health related quality of life will be assessed with EQ5D, and used for calculation of Quality Adjusted Life Years.

At baseline, 3-months, 6 months, 12 months and 24 months.
Cancer related fatigue
Tidsramme: At baseline, 3-months, 6 months, 12 months and 24 months.

Patient reported outcome cancer related fatigue is measured with Brief Fatigue Inventory.

At baseline, 3-months, 6 months, 12 months and 24 months.
Fear of movement
Tidsramme: At baseline, 3-months, 6 months, 12 months and 24 months.

Patient reported outcome Fear of movement is assessed with Cancer specific Tampa Scale for Kinesiophobia.

At baseline, 3-months, 6 months, 12 months and 24 months.
Changes in health
Tidsramme: At 3-months, 6 months, 12 months and 24 months.

Patient reported outcome Changes in health is assessed with Patient Global Impression of Change Scale.

At 3-months, 6 months, 12 months and 24 months.
Work ability
Tidsramme: At baseline, 3-months, 6 months, 12 months and 24 months.

Selected and adapted questions from Work Ability Index are used for assessing patient reported outcome work ability.

At baseline, 3-months, 6 months, 12 months and 24 months.
Self-efficacy for reducing sedentary behavior
Tidsramme: At baseline, 3-months, 6 months, 12 months and 24 months.

Study specific question is used for assessing patient reported outcome of Self-efficacy for reducing sedentary behavior.

At baseline, 3-months, 6 months, 12 months and 24 months.
Perceived support from peers
Tidsramme: At baseline, 3-months, 6 months, 12 months and 24 months.

Study specific question is used for assessing patient reported outcome of Perceived support from peers.

At baseline, 3-months, 6 months, 12 months and 24 months.

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Demographic variables
Tidsramme: Baseline

Study specific questions

Baseline
Diagnoses
Tidsramme: At baseline

Data regarding cancer diagnose and if any, co-morbid conditions, are gathered from medical records or Swedish national quality registers.

At baseline
Cancer treatment
Tidsramme: At baseline, 3-months, 6 months, 12 months and 24 months.

Data regarding planned and received oncological and surgical cancer treatment (type, dose, treatment start and end date of treatment) and any treatment related side-effects are gathered from medical records and Swedish quality registers.

At baseline, 3-months, 6 months, 12 months and 24 months.
Health care costs
Tidsramme: At baseline, 3-months, 6 months, 12 months and 24 months.

Data regarding outpatient visits, hospitalization and prescribed medication is gathered from Swedish national quality registers.

At baseline, 3-months, 6 months, 12 months and 24 months.
Costs of intervention
Tidsramme: At baseline, 3-months, 6 months, 12 months and 24 months.

Data regarding cost of application use and any cost for physical activity is gathered from study records and patient reported by study specific questions.

At baseline, 3-months, 6 months, 12 months and 24 months.
Sick leave
Tidsramme: At baseline, 3-months, 6 months, 12 months and 24 months.

Data regarding sick leave, i.e. total number of days being on sick leave gathered from the Swedish insurance fund (data on sick leave more than 14 days) and patient reported study specific questions (data on sick leave less than 14 days). Data will be gathered from 6 months prior baseline (study specific questions are administered at baseline and register data will be gathered at baseline but will include any data 6 months prior baseline).

At baseline, 3-months, 6 months, 12 months and 24 months.
Adherence
Tidsramme: At baseline, 3-months, 6 months, 12 months and 24 months.

Adherence to the intervention is assessed by Axivity accelometer and patient reported study specific questions.

At baseline, 3-months, 6 months, 12 months and 24 months.
Green house gas emissions
Tidsramme: At baseline, 3-months, 6 months, 12 months and 24 months.

Green house emissions will be compared between the intervention and control group and estimated using a life cycle analysis of the technology used in the intervention, self-reported changes in climate behavior, and emissions from healthcare.

At baseline, 3-months, 6 months, 12 months and 24 months.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Petra von Heideken Wågert, Professor, Mälardalen University

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. marts 2025

Primær færdiggørelse (Anslået)

31. december 2029

Studieafslutning (Anslået)

31. december 2030

Datoer for studieregistrering

Først indsendt

19. november 2024

Først indsendt, der opfyldte QC-kriterier

2. december 2024

Først opslået (Faktiske)

5. december 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

1. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

28. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 2020/1120

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Individual medical information may not be shared with other researchers if the research questions are not within the scope of the current approved Swedish Ethical Review Board application (and any amendments) for this research. Only pseudonymous information may be shared after approval has been provided from the Swedish Ethical Review Board.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .